Vyant Bio, Inc.
VYNT · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -69.7% | -7.9% | -45.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -32.6% | -69.1% | -84.2% | -27.4% |
| R&D Expenses | $2 | $2 | $2 | $2 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $2 | $3 | $3 |
| Sales & Mktg Exp. | $2 | $2 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $4 | $4 | $4 |
| Operating Income | -$3 | -$4 | -$4 | -$4 |
| % Margin | -7,604.3% | -2,421.7% | -2,627.9% | -1,451.2% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$3 | -$4 | -$4 | -$4 |
| Tax Expense | $7 | -$0 | $1 | $5 |
| Net Income | -$10 | -$3 | -$6 | -$9 |
| % Margin | -22,417.4% | -2,255.9% | -3,511.5% | -3,027.1% |
| EPS | -1.75 | -0.58 | -0.98 | -1.58 |
| % Growth | -201.7% | 40.8% | 38% | – |
| EPS Diluted | -1.75 | -0.58 | -0.98 | -1.58 |
| Weighted Avg Shares Out | 6 | 6 | 6 | 6 |
| Weighted Avg Shares Out Dil | 6 | 6 | 6 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$3 | -$4 | -$4 |
| % Margin | -6,884.8% | -2,250% | -2,489.1% | -1,371.9% |